Lytix Biopharma is a biotechnology company in the clinical stage that develops new cancer immunotherapies. The company's technology is based on research in antimicrobial peptides, a defense aimed at pathogens. Lytix Biopharma's main product, LTX-315, is an oncolytic peptide for the purpose of personalizing immunotherapy. The company conducts its research and operations in Oslo.